Category: Parkinson's Disease: Pathophysiology
Objective: To explore the association between Parkinson’s disease (PD) motor symptoms and CSF biomarkers for neuroinflammation and neurodegeneration.
Background: Previous in vivo and post mortem studies have suggested that neuroinflammation has a crucial role in PD. However, the relationship between neuroinflammation, neurodegeneration and clinical features of PD is poorly understood.
Method: The subject sample consisted of 16 individuals with PD (3 females, 13 males; mean age 66.5±6.3 years, mean disease duration 9±5.5 years) who underwent central spinal fluid (CSF) sampling to measure neuroinflammation and neurodegeneration biomarkers soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3-like 1 protein (YKL-40), neurogranin (NG). Motor symptom severity was evaluated with UPDRS-III in OFF stage. Subscores were calculated for rigidity (sum of UPDRS-III items 22a-e), body bradykinesia (items 24, 25, 26 and 31), tremor (sum of items 20a-e and 21a-b), and axial impairment (sum of items 27, 28, 29 and 30). Linear model was executed to evaluate association between CSF biomarkers and motor symptom scores. Age or gender adjustment were used if their association to biomarker was statistically significant.
Results: A positive correlation was observed between total UPDRS-III motor score and sTREM2 (r=0.6, p=0.014) while no significant associations were observed with NG (r=0.45, p=0.08) or YKL-40 (p=0.15). In motor subscore analyses both bradykinesia (r=0.78, p<0.001, Fig 1A) and axial impairment (r=0.68, p<0.01, Fig 1B) increased significantly with higher sTREM2. No statistically significant correlations were observed between tremor and rigidity subscores and CSF biomarkers or with disease duration and CSF biomarkers (p>0.05).
Conclusion: Bradykinesia and axial impairment were associated with increased levels of CSF sTREM2, a biomarker for neuroinflammation.
To cite this abstract in AMA style:
A. Brück, R. Ajalin, H. Al-Abdulrasul, H. Zetterberg, K. Blennow, E. Löyttyniemi, J. Rinne. Axial impairment and bradykinesia are related to increased CSF sTREM2, a neuroinflammation biomarker, in Parkinson’s disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/axial-impairment-and-bradykinesia-are-related-to-increased-csf-strem2-a-neuroinflammation-biomarker-in-parkinsons-disease/. Accessed October 23, 2026.« Back to 2023 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/axial-impairment-and-bradykinesia-are-related-to-increased-csf-strem2-a-neuroinflammation-biomarker-in-parkinsons-disease/